Adenosine 5’monophosphate-activated protein kinase activation reduces the risks of psoriasis and its comorbidities: a Mendelian randomization study in the UK Biobank
Authors' conclusion
AMPK activation may protect against LOPs and associated ischemic heart disease in men.
Study context
- Population
- UK Biobank participants; psoriasis split into early-onset and late-onset at 60 years9,126 EOP and 3324 LOP
- Participants
- 407,159 participants
- Comparison
- Higher vs lower AMPK genetic risk score
- Outcome
- Risk of psoriasis (early-onset and late-onset), its comorbidities and mortality
Methodological detailsUK Biobank, genetic instrument of 44 HbA1c-associated SNPs as proxy for AMPK genetic risk score, log-binomial models
- UK Biobank
- Genetic instrument of 44 HbA1c-associated SNPs as proxy for AMPK genetic risk score
- Log-binomial models
Performance
As reported in the abstract
Late-onset psoriasis in men, per AMPK genetic risk score
RR (95% CI 1.022-1.236); 12.4% increase in LOP risk in men
1.124
Further findings
Ischaemic heart disease in male psoriasis patients, per AMPK genetic risk score
- RR
- 1.217 (95% CI 1.062-1.395)
Original publication
Adenosine 5’monophosphate-activated protein kinase activation reduces the risks of psoriasis and its comorbidities: a Mendelian randomization study in the UK Biobank. Rheumatology (Oxford). Published 6 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →